Search Clinical Trials in the European Union

Duration
11-15 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 306 trials

Eculizumab for Hypertensive Emergency-Associated Kidney Condition

We are studying whether Eculizumab can improve kidney function in patients with a severe kidney condition linked to high blood pressure. This trial will help us understand its effects on dialysis needs and overall health.

Atypical Hemolytic Uremic Syndrome (aHUS)1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ovarian Cancer: Mirvetuximab Soravtansine Study

We are evaluating different dosing schedules of mirvetuximab soravtansine for patients with advanced ovarian, peritoneal, or fallopian tube cancers. This study aims to find the safest and most effective way to administer the treatment.

Advanced Ovarian and Fallopian Tube Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

Knee Osteoarthritis: KBP-336 Medication Study

We are testing a new medication for obese individuals with knee osteoarthritis to see if it helps reduce weight and pain. The study will also look at other symptoms and overall safety compared to a placebo.

Knee OsteoarthritisObesity6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Psoriatic Arthritis: JNJ-77242113 Study

We are testing a new medication for people with active psoriatic arthritis who have used other biologic treatments. The study aims to see if it can reduce symptoms better than a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Opioid Use Disorder: Daridorexant Treatment

We are studying whether daridorexant can help reduce illicit substance use in people with opioid use disorder already on buprenorphine. The trial also looks at improvements in cravings, withdrawal symptoms, and overall treatment retention.

Opioid Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsStandard MedicinesPsychiatry

Heart Inflammation: Immunosuppressive Treatment Study

We are studying whether a combination of prednisone and azathioprine can improve heart function in patients with inflammatory heart disease. This trial compares the treatment to a placebo to see if it offers any benefits.

Myocarditis>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCardiologyInternal Medicine